Effect of Antibiotic Treatment on Serum PSA and Percent Free PSA Levels in Patients with Biochemical Criteria for Prostate Biopsy and Previous Lower Urinary Tract Infections

Lorente, José A.; Arango, O.; Bielsa, Oscar; Cortadellas, R.; Gelabert-Más, Antoni

doi:10.1177/172460080201700202

Cited by 27 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scattoni et al, 16 compared the pathology results of prostatectomy with the preoperative f-PSA/t-PSA ratio and found a decreased ratio in the presence of histological signs of acute prostatitis. Lorente et al 17 found significant variations in t-PSA and f-PSA/ t-PSA ratios in patients with benign prostatic hyperplasia (BPH)-associated prostatitis and not in patients with BPH or cancer. On the contrary, Ornstein et al 18 did not find any change in f-PSA/t-PSA ratio in prostatitis.…”

Section: Discussionmentioning

confidence: 99%

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

Serretta

Catanese

Daricello

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P ¼ 0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

show abstract

Section: Discussionmentioning

confidence: 99%

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

Serretta

Catanese

Daricello

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Although these genes had been shown to be important in the development and metastasis of prostate cancer, it is not clear whether they can be used as biomarkers to predict the malignant tendencies and the outcome of the patients. The routinely used prostate cancer marker Prostate Specific Antigen (PSA) is a very useful tool to screen prostatic diseases, but it can be affected by many other factors 27 and moreover, it merely reflects the prostatic volume. Although it is a good indictor of the size changes in the prostate gland, PSA alone cannot accurately predict the nature of the prostate cells, nor distinguish between the benign and malignant status.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of osteopontin expression in human prostate cancer

Forootan

Foster

Aachi

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

To test the hypothesis that expression of osteopontin (OPN), an integrin-binding glycoprotein, can independently predict the potential aggressiveness of prostate cancer, the status of OPN expression in benign and malignant prostate cancer cell lines and tissues was analysed by Western blot and immunohistochemistry. Amongst the four prostate cell lines analysed, the level of OPN expressed in the benign PNT-2 cells was set at 1, the relative level of OPN expressed in the weakly malignant cell line LNCaP was increased to 1.5. In the highly malignant cell lines Du-145 and PC-3, the level of OPN expression was further increased to 2.9 and 4.4, respectively. An increased expression of OPN was also observed in the prostate tissue samples. When the level of OPN in normal tissue was set at 1, its level in benign prostate hyperplasia (BPH) was similar at 0.99 6 0.2, whereas the OPN level in the highly malignant carcinoma tissue was greatly increased by nearly 6-fold to 5.9 6 0.3. Amongst the 116 cases examined immunocytochemically, of the 10 normal cases, 3 (30%) were unstained and 7 (70%) stained weakly positive (1). Amongst the 36 BPH samples, 32 (89%) stained weakly positive (1) and 4 (11%) were unstained (2). For the 70 carcinomas analysed, 31 (44%) stained strongly positive (111), 20 (29%) stained moderately positive (11) and 19 (27%) stained weakly positive (1). These results showed that the level of OPN expressed between the normal and the BPH samples was not significantly different (Fisher's exact test, p 5 0.16). However, in comparison to that in the BPH samples, the expression of OPN in the carcinoma tissues was significantly increased (Chi-square test, p < 0.0001). Kaplan-Meier survival analysis showed that the increased level of OPN expression was significantly (n 5 70, p 5 0.03) associated with reduced survival time of the patients. The OPN expression was increased with the increasing Gleason scores of the carcinomas (Chi-square test, p < 0.001). The results in our study support our hypothesis and suggest that the increased OPN level may be involved in the malignant transformation of prostate epithelial cells and OPN expression level is an important determinant for patient survival. ' 2005 Wiley-Liss, Inc.Key words: prostate carcinoma; osteopontin; benign prostate hyperplasia (BPH); Gleason scores; patient survival Prostate cancer has become the most common male cancer and the second leading cause of death from male malignant disease in the United States and Europe, and this disease kills more than 40,000 men per year in the developed world. 1,2 Despite the increasing incidence, the molecular basis of prostate cancer progression, invasion and metastasis is still not fully understood. The complicated molecular pathology of prostate cancer may involve a series of sequential genetic events, which cause the initiation and progression of the malignant changes of prostate epithelial cells. The complicated genetic events responsible for tumorigenicity and metastasis of prostate cancer may be classified in a simple ...

show abstract

“…We subsequently back-calculated the CV b by subtracting CV a from CV t : CV b ϭ ͌ CV t 2 Ϫ CV a 2 (7 ). Fifteen studies reported considerable variability of serial tPSA concentrations, but it was impossible to derive the CV b because of sufficient information on CV t and CV a was lacking (33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47).…”

Section: Biological Variation Estimatesmentioning

confidence: 99%

Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice

Sölétormos¹,

et al. 2005

View full text Add to dashboard Cite

Background:The objectives of this study were to determine whether a single result for total prostate-specific antigen (tPSA) can be used confidently to guide the need for prostate biopsy and by how much serial tPSA measurements must differ to be significant. tPSA measurements include both analytical and biological components of variation. The European Group on Tumor Markers conducted a literature survey to determine both the magnitude and impact of biological variation on single, the mean of replicate, and serial tPSA measurements. Methods: The survey yielded 27 studies addressing the topic, and estimates for the biological variation of tPSA could be derived from 12 of these studies. Results: The mean biological variation was 20% in the concentration range 0.1-20 g/L for men over 50 years. The biological variation means that the one-sided 95% confidence interval (CI) of the dispersion for a single tPSA

show abstract

Effect of Antibiotic Treatment on Serum PSA and Percent Free PSA Levels in Patients with Biochemical Criteria for Prostate Biopsy and Previous Lower Urinary Tract Infections

Cited by 27 publications

References 21 publications

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

Prognostic significance of osteopontin expression in human prostate cancer

Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice

Contact Info

Product

Resources

About